OspreyBio specializes in advanced biotechnological tools aimed at simplifying the development of multigenic systems for research and therapeutic applications. Central to their offerings is the CloneCard, a pioneering multigene construction tool that allows researchers to create complex multitarget systems efficiently. Each CloneCard contains eight genes, enabling the simultaneous manipulation of multiple pathways, which can lead to innovative approaches in gene and cell therapy. The Bird of Prey (BoP) system complements the CloneCard by providing a standardized vector format and straightforward protocols, making it accessible for use in various mammalian cell types. This modular DNA design facilitates the creation of multi-effector genes and transcription units, streamlining the research process.

In addition to the CloneCard and BoP system, OspreyBio offers a range of enzymes and quality control tools to enhance the reliability of genetic experiments. Their unique "Uber" REQC vector tests the functionality of numerous restriction enzymes, helping researchers avoid costly errors in their experiments. The company also provides ready-to-use plasmids that can be stored at ambient temperatures, eliminating the need for specialized storage conditions. With a focus on continuous innovation, OspreyBio is committed to expanding its catalog of biotools, thereby supporting researchers in their quest for breakthroughs in the life sciences.

United States

OspreyBio is a newly launched and first gene-and-cell-therapy-centric biotools company. Our core principle is to "Think Multigenic". From tools to make multi-effector AAVs to 8-gene (or more) constructs, Osprey is expanding its portfolio of products related to building multigenes, delivering large DNA, and reducing manufacturing costs to bring us all into the future of gene and cell therapy.

OspreyBio

Company Details